Sanuwave Health (NASDAQ:SNWV) Stock Price Down 1% – Should You Sell?

Sanuwave Health Inc. (NASDAQ:SNWV) fell 1% on Wednesday . The stock traded as low as $26.10 and last traded at $26.43. 50,442 shares changed hands during trading, an increase of 5% from the average session volume of 48,110 shares. The stock had previously closed at $26.70.

Analyst Upgrades and Downgrades

Several brokerages have commented on SNWV. Weiss Ratings reissued a “sell (d-)” rating on shares of Sanuwave Health in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Sanuwave Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Roth Mkm set a $53.00 price target on shares of Sanuwave Health and gave the company a “buy” rating in a research report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $54.00.

Sanuwave Health Trading Down 1.0%

The firm has a market capitalization of $226.77 million, a P/E ratio of -20.33 and a beta of 1.34. The business’s 50 day simple moving average is $30.54 and its two-hundred day simple moving average is $33.75.

Sanuwave Health (NASDAQ:SNWV) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $0.14. The firm had revenue of $11.45 million during the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SNWV. Opaleye Management Inc. increased its holdings in Sanuwave Health by 0.8% in the 2nd quarter. Opaleye Management Inc. now owns 980,000 shares of the company’s stock worth $32,203,000 after buying an additional 7,998 shares in the last quarter. Geode Capital Management LLC bought a new position in Sanuwave Health during the 2nd quarter valued at about $5,184,000. CenterBook Partners LP boosted its holdings in shares of Sanuwave Health by 528.7% during the 3rd quarter. CenterBook Partners LP now owns 87,947 shares of the company’s stock valued at $3,296,000 after acquiring an additional 73,959 shares during the last quarter. Stonebridge Wealth Management LLC bought a new stake in shares of Sanuwave Health in the second quarter worth approximately $1,696,000. Finally, Rice Hall James & Associates LLC bought a new stake in shares of Sanuwave Health in the third quarter worth approximately $1,023,000. 42.53% of the stock is owned by institutional investors.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.